Atea Pharmaceuticals Inc.

7.13+0.1900+2.74%Vol 2.00M1Y Perf -70.37%
Jun 24th, 2022 16:00 DELAYED
BID6.98 ASK7.60
Open6.97 Previous Close6.94
Pre-Market- After-Market7.13
 - -  - -%
Target Price
8.67 
Analyst Rating
Hold 2.83
Potential %
21.60 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★★     70.07
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★★     70.71
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
4.38 
Earnings Rating
Market Cap593.62M 
Earnings Date
11th Aug 2022
Alpha0.00 Standard Deviation0.33
Beta-0.72 

Today's Price Range

6.927.42

52W Range

5.3146.91

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
9.69%
1 Month
-2.86%
3 Months
3.18%
6 Months
-21.73%
1 Year
-70.37%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
AVIR7.130.19002.74
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.58-0.5112.07
Q04 20210.331.34306.06
Q03 2021-0.05-0.34-580.00
Q02 20210.010.02100.00
Q01 2021-0.060.34666.67
Q03 2020-1.06-1.74-64.15
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date11th Aug 2022
Estimated EPS Next Report-0.49
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume2.00M
Shares Outstanding83.26K
Shares Float63.21M
Trades Count6.78K
Dollar Volume14.29M
Avg. Volume860.12K
Avg. Weekly Volume996.89K
Avg. Monthly Volume879.22K
Avg. Quarterly Volume704.24K

Atea Pharmaceuticals Inc. (NYSE: AVIR) stock closed at 7.13 per share at the end of the most recent trading day (a 2.74% change compared to the prior day closing price) with a volume of 2.00M shares and market capitalization of 593.62M. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 19 people. Atea Pharmaceuticals Inc. CEO is Jean-Pierre Sommadossi.

The one-year performance of Atea Pharmaceuticals Inc. stock is -70.37%, while year-to-date (YTD) performance is -20.25%. AVIR stock has a five-year performance of %. Its 52-week range is between 5.31 and 46.9099, which gives AVIR stock a 52-week price range ratio of 4.38%

Atea Pharmaceuticals Inc. currently has a PE ratio of 15.80, a price-to-book (PB) ratio of 0.95, a price-to-sale (PS) ratio of 1.93, a price to cashflow ratio of 1.80, a PEG ratio of 2.32, a ROA of 6.21%, a ROC of 7.58% and a ROE of 7.65%. The company’s profit margin is 16.96%, its EBITDA margin is 23.00%, and its revenue ttm is $285.38 Million , which makes it $3.43 revenue per share.

Of the last four earnings reports from Atea Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.49 for the next earnings report. Atea Pharmaceuticals Inc.’s next earnings report date is 11th Aug 2022.

The consensus rating of Wall Street analysts for Atea Pharmaceuticals Inc. is Hold (2.83), with a target price of $8.67, which is +21.60% compared to the current price. The earnings rating for Atea Pharmaceuticals Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Atea Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Atea Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 27.91, ATR14 : 0.49, CCI20 : -25.58, Chaikin Money Flow : -0.15, MACD : -0.07, Money Flow Index : 68.59, ROC : -11.76, RSI : 51.05, STOCH (14,3) : 48.61, STOCH RSI : 1.00, UO : 38.13, Williams %R : -51.39), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Atea Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (25.00 %)
1 (25.00 %)
1 (25.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (50.00 %)
2 (50.00 %)
2 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (25.00 %)
1 (25.00 %)
1 (25.00 %)
Summary RatingHold
2.83
Hold
2.83
Hold
2.83

Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Inc is a clinical stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The company's medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science.

CEO: Jean-Pierre Sommadossi

Telephone: +1 857 284-8891

Address: 125 Summer Street, Boston 02110, MA, US

Number of employees: 19

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

67%33%

Bearish Bullish

58%42%

TipRanks News for AVIR

Wed, 02 Mar 2022 16:47 GMT Atea Pharmaceuticals (AVIR) Gets a Hold Rating from J.P. Morgan

- TipRanks. All rights reserved.

Sun, 27 Feb 2022 11:58 GMT Atea Pharmaceuticals: Stumbling Over Rising Costs

- TipRanks. All rights reserved.

Wed, 16 Feb 2022 12:43 GMT Atea Pharmaceuticals (AVIR) Receives a Hold from Leerink Partners

- TipRanks. All rights reserved.

Sat, 08 Jan 2022 12:06 GMT Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Atea Pharmaceuticals (AVIR) and LAVA Therapeutics (LVTX)

- TipRanks. All rights reserved.

News

Stocktwits